Thai FDA Adds Five Approved Probiotic Strains

Thai FDA has widened the door for probiotic supplement and functional food companies with a notification that took effect February 13, 2026 (B.E. 2569). Titled "Notification on Criteria and Guidelines for the Use of Probiotic Microorganisms in Food (No. 2)," it adds five internationally validated strains to Thailand's approved probiotic list: Bacillus subtilis DE111, Lacticaseibacillus casei Shirota, Lacticaseibacillus casei DN-114001, Lactiplantibacillus plantarum 299V, and Lactococcus lactis subsp. cremoris FC. For any company that has been holding off on a probiotic launch because of the documentation burden, this notification changes the calculation.

Strains With Track Records, Now on the List

Each of these five strains carries substantial safety and efficacy literature from international markets. Bacillus subtilis DE111 is a fixture in sports nutrition and digestive health formulations. Lacticaseibacillus casei Shirota is the foundational strain behind Yakult products sold across Asia, giving it an especially long consumer safety history in the region. Lactiplantibacillus plantarum 299V has a deep body of clinical research supporting gastrointestinal applications. Before this notification, using any strain not already on Thai FDA's approved list meant assembling a full safety dossier from primary research, covering in vitro and in vivo safety data, antibiotic resistance profiling, and evidence of safe use history. That process alone could extend notification timelines by six months or more, and it required specialist microbiological documentation that many smaller supplement companies simply did not have the capacity to produce. With these five strains now listed, companies can reference approved status directly instead of rebuilding that safety case from scratch.

What Actually Gets Easier, and What Does Not

The documentation burden does not disappear, it shifts. Once a strain is on the approved list, the compliance work moves from establishing safety to confirming identity and maintaining GMP standards. Manufacturers still need to demonstrate that the strain in their product matches the approved designation precisely, that the manufacturing process holds strain viability to the labeled CFU count through the end of shelf life, and that the finished product meets Thai FDA's microbiological quality standards. None of that is a novel documentation challenge; it is standard GMP and quality control work that most established manufacturers already have systems for.

The practical upshot is a genuinely faster path to market for products built around these strains. Thailand's probiotic supplement market has grown steadily alongside post-pandemic consumer interest in immune and digestive health, and this update brings Thai FDA's approved list more in line with regional peers like Singapore and Japan, both of which have moved faster on strain approvals in recent years.

Where to Focus Before You Submit

Approved list status covers the named strain designation exactly as written, subspecies and strain code included, so the first step is getting a Certificate of Analysis and strain identity documentation from your ingredient supplier confirming an exact match before relying on listed status in a Thai FDA submission. Next, look hard at your stability data. Thai FDA's probiotic labeling requirements set CFU count claims at end of shelf life, and if your current stability program's testing intervals do not cover shelf life extremes for Thailand's climate, high heat and high humidity in particular, that protocol needs updating before submission rather than after a compliance issue surfaces. If you already have notified probiotic products built around a full safety dossier for one of these five strains, it is worth reviewing whether a re-notification aligned with the new criteria simplifies your ongoing compliance obligations. And keep watching the list itself: Thai FDA has signaled interest in further additions as international safety data accumulates, so companies with strains still outside the approved list may want to track upcoming notifications or even contribute safety data toward future additions.

DeeMED Consulting works with probiotic manufacturers to scope Thai FDA submissions against the technical requirements reviewers actually apply, not just the baseline checklist. If your product pipeline includes one of these newly approved strains, our GMP compliance and manufacturing team can assess your current documentation and map out the fastest compliant route to market.